Literature DB >> 17566838

Up-to-date management of lymph node metastasis and the role of tailored lymphadenectomy in cervical cancer.

Noriaki Sakuragi1.   

Abstract

Lymph node metastasis (LNM), together with parametrial infiltration and positive surgical margins, is an important prognostic factor in cervical cancer. The incidence of LNM increases with International Federation of Gynecology and Obstetrics (FIGO) stage, with rates being 12%-22% in stage Ib, 10%-27% in stage IIa, and 34%-43% in stage IIb. Radical hysterectomy and pelvic lymphadenectomy are widely used treatments for early-stage (Ib to IIa) cervical cancer, as well as for stage IIb disease, in some European and Asian countries. In several types of cancer, the therapeutic significance of systematic lymphadenectomy has been demonstrated by recent reports showing that a larger number of lymph nodes removed relates to better survival. In cervical cancer, a significant relationship between the number of lymph nodes removed and disease-free survival has been reported in node-positive patients. Preoperative evaluation of nodal status with computed tomography (CT), magnetic resonance imaging (MRI), and positron emission tomography (PET) imaging techniques is not sensitive enough to replace the histological examination of dissected nodes. The sentinel node procedure may be an alternative to systematic lymphadenectomy to reduce treatment-related morbidity, but more work on this is needed. Although the presence of LNM does not change FIGO staging, it will modulate postoperative therapy. Progression-free and overall survivals were significantly improved by the addition of chemotherapy to adjuvant radiotherapy after radical hysterectomy and lymphadenectomy. Adjuvant chemotherapy combined solely with radical hysterectomy and systematic lymphadenectomy may also provide a survival benefit. In conclusion, efforts to establish more tailored surgical strategies, by introducing advanced imaging technologies and molecular diagnostic procedures, are needed for cervical cancer.

Entities:  

Mesh:

Year:  2007        PMID: 17566838     DOI: 10.1007/s10147-007-0661-2

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  89 in total

Review 1.  Patients with locally advanced cervical cancer should not undergo routine pretreatment surgical staging.

Authors:  F Mota; C De Oliveira
Journal:  Eur J Gynaecol Oncol       Date:  2006       Impact factor: 0.196

2.  Prognostic factors and impacts of adjuvant therapy in early-stage cervical carcinoma with pelvic node metastases.

Authors:  C H Lai; H C Chang; T C Chang; S Hsueh; S G Tang
Journal:  Gynecol Oncol       Date:  1993-12       Impact factor: 5.482

3.  A systematic nerve-sparing radical hysterectomy technique in invasive cervical cancer for preserving postsurgical bladder function.

Authors:  N Sakuragi; Y Todo; M Kudo; R Yamamoto; T Sato
Journal:  Int J Gynecol Cancer       Date:  2005 Mar-Apr       Impact factor: 3.437

4.  Tumor size, depth of invasion, and grading of the invasive tumor front are the main prognostic factors in early squamous cell cervical carcinoma.

Authors:  G B Kristensen; V M Abeler; B Risberg; C Trop; M Bryne
Journal:  Gynecol Oncol       Date:  1999-08       Impact factor: 5.482

5.  Low value of [18F]-fluoro-2-deoxy-D-glucose positron emission tomography in primary staging of early-stage cervical cancer before radical hysterectomy.

Authors:  Hung-Hsueh Chou; Ting-Chang Chang; Tzu-Chen Yen; Koon-Kwan Ng; Swei Hsueh; Shih-Ya Ma; Chee-Jen Chang; Huei-Jean Huang; Angel Chao; Tzu-I Wu; Shih-Ming Jung; Yen-Ching Wu; Cheng-Tao Lin; Kuan-Gen Huang; Chyong-Huey Lai
Journal:  J Clin Oncol       Date:  2006-01-01       Impact factor: 44.544

6.  A multivariate analysis of blood vessel and lymph vessel invasion as predictors of ovarian and lymph node metastases in patients with cervical carcinoma.

Authors:  N Sakuragi; N Takeda; H Hareyama; T Fujimoto; Y Todo; K Okamoto; M Takeda; S i Wada; R Yamamoto; S Fujimoto
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

7.  Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix.

Authors:  W A Peters; P Y Liu; R J Barrett; R J Stock; B J Monk; J S Berek; L Souhami; P Grigsby; W Gordon; D S Alberts
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

Review 8.  Lymphatic mapping for gynecologic malignancies.

Authors:  Emmanuel Barranger; Emile Darai
Journal:  Semin Oncol       Date:  2004-06       Impact factor: 4.929

9.  Identification of micrometastases in histologically negative lymph nodes of early-stage cervical cancer patients.

Authors:  Scott E Lentz; Laila I Muderspach; Juan C Felix; Wei Ye; Susan Groshen; Charles A Amezcua
Journal:  Obstet Gynecol       Date:  2004-06       Impact factor: 7.661

10.  Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by immunohistochemical analysis.

Authors:  Margrit M Juretzka; Kristin C Jensen; Teri A Longacre; Nelson N Teng; Amreen Husain
Journal:  Gynecol Oncol       Date:  2004-04       Impact factor: 5.482

View more
  42 in total

1.  Cervical adenoid basal carcinoma associated with invasive squamous cell carcinoma: a report of rare co-existence and review of literature.

Authors:  Boonlert Viriyapak; Sung Taek Park; Ah Won Lee; Jong Sup Park; Chung Won Lee; Min Jong Song; Soo Young Hur
Journal:  World J Surg Oncol       Date:  2011-10-18       Impact factor: 2.754

Review 2.  Present status of sentinel lymph node biopsy in cervical cancer.

Authors:  Ariel Gustavo Glickman; Sergio Valdes; Blanca Gil-Ibañez; Pilar Paredes; Karen Sttephannía Cortés; Aureli Angel Torné Blade
Journal:  Rep Pract Oncol Radiother       Date:  2018-05-09

Review 3.  Progress in the Study of Lymph Node Metastasis in Early-stage Cervical Cancer.

Authors:  Bang-Xing Huang; Fang Fang
Journal:  Curr Med Sci       Date:  2018-08-20

4.  ADC Histogram Analysis of Cervical Cancer Aids Detecting Lymphatic Metastases-a Preliminary Study.

Authors:  Stefan Schob; Hans Jonas Meyer; Nikolaos Pazaitis; Dominik Schramm; Kristina Bremicker; Marc Exner; Anne Kathrin Höhn; Nikita Garnov; Alexey Surov
Journal:  Mol Imaging Biol       Date:  2017-12       Impact factor: 3.488

5.  Clinical significance of microRNA expressions in diagnosing uterine cancer and predicting lymph node metastasis.

Authors:  Changlong Hou; Guosheng Tan; Shiting Feng
Journal:  Tumour Biol       Date:  2014-07-31

6.  MicroRNA-877 is downregulated in cervical cancer and directly targets MACC1 to inhibit cell proliferation and invasion.

Authors:  Fanxu Meng; Jian Ou; Jinyu Liu; Xindi Li; Yanli Meng; Ling Yan; Ping Deng; Baosheng Sun
Journal:  Exp Ther Med       Date:  2019-09-09       Impact factor: 2.447

7.  Long-term outcomes of postoperative taxane/platinum chemotherapy for early stage cervical cancer: a retrospective study.

Authors:  Mika Okazawa-Sakai; Takanori Yokoyama; Etsuko Fujimoto; Shinichi Okame; Yuko Shiroyama; Takashi Yokoyama; Kazuhiro Takehara
Journal:  Int J Clin Oncol       Date:  2018-02-14       Impact factor: 3.402

8.  Risk factors for lower-limb lymphedema after surgery for cervical cancer.

Authors:  Yoko Ohba; Yukiharu Todo; Noriko Kobayashi; Masanori Kaneuchi; Hidemichi Watari; Mahito Takeda; Satoko Sudo; Masataka Kudo; Hidenori Kato; Noriaki Sakuragi
Journal:  Int J Clin Oncol       Date:  2011-01-07       Impact factor: 3.402

9.  Detection of sentinel lymph nodes in minimally invasive surgery using indocyanine green and near-infrared fluorescence imaging for uterine and cervical malignancies.

Authors:  Elizabeth L Jewell; Juan Juan Huang; Nadeem R Abu-Rustum; Ginger J Gardner; Carol L Brown; Yukio Sonoda; Richard R Barakat; Douglas A Levine; Mario M Leitao
Journal:  Gynecol Oncol       Date:  2014-02-28       Impact factor: 5.482

10.  Adjuvant chemotherapy following concurrent chemoradiotherapy for uterine cervical cancer with lymphadenopathy.

Authors:  Akiko Abe; Hiroyuki Furumoto; Masato Nishimura; Minoru Irahara; Hitoshi Ikushima
Journal:  Oncol Lett       Date:  2011-12-06       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.